Table 2.
Clinical features of four patients with hepatic irAE.
| Case | Age | Sex | Primary lesion | ICIs | Duration of ICIs until liver injury, days | Clinical symptoms | The pattern of liver injury | Histologic pattern of liver injury | Therapy |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 75 | M | Hypopharyngeal | NIVO | 14 | Loss of appetite | Hepatocellular | Panlobular hepatitis Moderate fibrosis |
Steroid + UDCA |
| 2 | 52 | M | Renal | NIVO + IPI | 63 | Fever | Hepatocellular | Panlobular hepatitis | Steroid + UDCA |
| 3 | 72 | M | Esophageal | NIVO | 360 | No symptoms | Mixed | Portal >zone 3 hepatitis | Steroid |
| 4 | 58 | M | Gastric | NIVO | 56 | Abdominal pain | Cholestatic | Portal hepatitis cholangitis | Steroid + UDCA |
irAEs: immune-related adverse events; ICIs: immune checkpoint inhibitors; NIVO: nivolumab; IPI: ipilimumab; UDCA: ursodeoxycholic acid.